BR112012002981A2 - sistema de liberação de fármaco oftálmico contendo fosfolipídio e colesterol. - Google Patents

sistema de liberação de fármaco oftálmico contendo fosfolipídio e colesterol.

Info

Publication number
BR112012002981A2
BR112012002981A2 BR112012002981A BR112012002981A BR112012002981A2 BR 112012002981 A2 BR112012002981 A2 BR 112012002981A2 BR 112012002981 A BR112012002981 A BR 112012002981A BR 112012002981 A BR112012002981 A BR 112012002981A BR 112012002981 A2 BR112012002981 A2 BR 112012002981A2
Authority
BR
Brazil
Prior art keywords
cholesterol
delivery system
drug delivery
system containing
ophthalmic drug
Prior art date
Application number
BR112012002981A
Other languages
English (en)
Other versions
BR112012002981B8 (pt
BR112012002981B1 (pt
Inventor
Keelung Hong
Luke S Guo
Po-Chun Chang
Sheue-Fang Shih
Yun-Long Tseng
Original Assignee
Taiwan Liposome Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Taiwan Liposome Co Ltd filed Critical Taiwan Liposome Co Ltd
Publication of BR112012002981A2 publication Critical patent/BR112012002981A2/pt
Publication of BR112012002981B1 publication Critical patent/BR112012002981B1/pt
Publication of BR112012002981B8 publication Critical patent/BR112012002981B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/28—Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/38—Albumins
    • A61K38/385—Serum albumin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts, ocular implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Ophthalmology & Optometry (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
BR112012002981A 2009-08-10 2010-01-29 sistema de liberação de fármaco oftálmico contendo fosfolipídio e colesterol BR112012002981B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US12/538,435 US8956600B2 (en) 2009-08-10 2009-08-10 Ophthalmic drug delivery system containing phospholipid and cholesterol
US12/538,435 2009-08-10
PCT/US2010/022487 WO2011019410A1 (en) 2009-08-10 2010-01-29 Ophthalmic drug delivery system containing phospholipid and cholesterol

Publications (3)

Publication Number Publication Date
BR112012002981A2 true BR112012002981A2 (pt) 2016-04-19
BR112012002981B1 BR112012002981B1 (pt) 2020-12-01
BR112012002981B8 BR112012002981B8 (pt) 2021-05-25

Family

ID=43534994

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112012002981A BR112012002981B8 (pt) 2009-08-10 2010-01-29 sistema de liberação de fármaco oftálmico contendo fosfolipídio e colesterol

Country Status (18)

Country Link
US (4) US8956600B2 (pt)
EP (3) EP3275445A1 (pt)
JP (2) JP5816623B2 (pt)
KR (2) KR101787775B1 (pt)
CN (2) CN102573800B (pt)
AU (1) AU2010282983B2 (pt)
BR (1) BR112012002981B8 (pt)
CA (1) CA2769929C (pt)
CY (2) CY1121472T1 (pt)
DK (2) DK2813229T3 (pt)
ES (2) ES2699178T3 (pt)
HK (2) HK1172564A1 (pt)
NZ (2) NZ623450A (pt)
PT (2) PT2813229T (pt)
RU (1) RU2572213C2 (pt)
TW (1) TWI515008B (pt)
WO (1) WO2011019410A1 (pt)
ZA (1) ZA201201034B (pt)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8956600B2 (en) * 2009-08-10 2015-02-17 Taiwan Liposome Co. Ltd. Ophthalmic drug delivery system containing phospholipid and cholesterol
TW201336526A (zh) * 2012-01-31 2013-09-16 參天製藥股份有限公司 非水性液體組成物
JP6231995B2 (ja) * 2012-02-10 2017-11-15 タイワン リポソーム カンパニー リミテッド 眼の疾患の合併症を低減するための薬学的組成物
JP6044920B2 (ja) * 2012-03-27 2016-12-14 国立研究開発法人農業・食品産業技術総合研究機構 酸化ｌｄｌ受容体に作用するリポソーム
NZ703532A (en) * 2012-07-05 2018-02-23 Taiwan Liposome Co Ltd Methods of treating arthritis
EA201590025A1 (ru) * 2012-07-17 2015-06-30 Риджентс оф дзе Юниверсити оф Мичиган Нехирургический способ лечения катаракты
US11458199B2 (en) 2012-08-21 2022-10-04 Opko Pharmaceuticals, Llc Liposome formulations
KR102177437B1 (ko) * 2012-08-21 2020-11-12 옵코 파마슈티칼스, 엘엘씨 리포좀 제제
EA022183B1 (ru) * 2012-12-24 2015-11-30 Общество С Ограниченной Ответственностью "Технология Лекарств" Способ получения липосомальной формы цитохрома с
US10342846B2 (en) 2013-02-04 2019-07-09 University Of Notre Dame Du Lac Nanoparticle drug delivery systems
WO2014196621A1 (ja) * 2013-06-07 2014-12-11 Ｋｔｎバイオテック株式会社 抗癌剤
US9895312B2 (en) * 2014-04-08 2018-02-20 Pablo E. Vivas-Mejia Nanoliposomal c-MYC-siRNA inhibits in vivo tumor growth of cisplatin-resistant ovarian cancer
CN108712911A (zh) * 2015-12-30 2018-10-26 科达制药股份有限公司 抗体及其缀合物
AU2017205337B2 (en) * 2016-01-07 2022-09-08 Tesorx Pharma, Llc Formulations for treating bladder cancer
WO2017188818A1 (en) 2016-04-29 2017-11-02 Enceladus Pharmaceuticals B.V. Liposomal corticosteroids for topical injection in inflamed lesions or areas
IL264842B (en) 2016-08-18 2022-08-01 Troy Bremer Delivery of urea to macular and retinal cells using liposome constructs
US20220133697A1 (en) * 2018-12-05 2022-05-05 Aldeyra Therapeutics, Inc. Injectable formulations
US11912784B2 (en) 2019-10-10 2024-02-27 Kodiak Sciences Inc. Methods of treating an eye disorder
CN110743035A (zh) * 2019-11-06 2020-02-04 广西大学 一种智能抗菌的水凝胶的制备方法及其应用
GB201917487D0 (en) * 2019-11-29 2020-01-15 Oxular Ltd Methods for the treatment of retinoblastoma
TW202302115A (zh) 2021-03-05 2023-01-16 台灣微脂體股份有限公司 具有降低副作用的藥學組成物及其使用方法

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2004A (en) * 1841-03-12 Improvement in the manner of constructing and propelling steam-vessels
US550960A (en) * 1895-12-10 Island
US4804539A (en) * 1986-07-28 1989-02-14 Liposome Technology, Inc. Ophthalmic liposomes
AU598958B2 (en) 1987-11-12 1990-07-05 Vestar, Inc. Improved amphotericin b liposome preparation
US4865846A (en) 1988-06-03 1989-09-12 Kaufman Herbert E Drug delivery system
BE1001869A3 (fr) * 1988-10-12 1990-04-03 Franz Legros Procede d'encapsulation liposomiale d'antibiotiques aminoglucosidiques, en particulier de la gentamycine.
JPH07503952A (ja) 1992-02-12 1995-04-27 ジヤンセン・シラグ・ソチエタ・ペル・アチオニ リポソームピロキシカム組成物
TR199701683A3 (tr) 1997-12-18 2001-06-21 Eldem Tuerkan Oküler ve parenteral polimer kapli lipozomal ilaç tasiyici sistemler.
KR100816572B1 (ko) * 1999-04-28 2008-03-24 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 항-ｖｅｇｆ 항체 및 이를 포함하는 약제학적 조성물
US6248353B1 (en) 1999-12-10 2001-06-19 Dade Behring Inc. Reconstitution of purified membrane proteins into preformed liposomes
DE10032627A1 (de) 2000-07-07 2002-01-17 Km Europa Metal Ag Verwendung einer Kupfer-Nickel-Legierung
WO2003000227A2 (en) 2001-06-25 2003-01-03 Yissum Research Development Company Of The Hebrew University Of Jerusalem A method for preparation of vesicles loaded with biological material and different uses thereof
US8946295B2 (en) * 2002-07-25 2015-02-03 Sunny Pharmtech Inc. Histone hyperacetylating agents for promoting wound healing and preventing scar formation
US20040224010A1 (en) 2002-11-15 2004-11-11 Optime Therapeutics, Inc. Ophthalmic liposome compositions and uses thereof
AU2003298738A1 (en) * 2002-11-26 2004-06-18 Su-Ming Chiang Liposomal formulations
JP2006248978A (ja) 2005-03-10 2006-09-21 Mebiopharm Co Ltd 新規なリポソーム製剤
US20070072933A1 (en) * 2005-09-26 2007-03-29 Peyman Gholam A Delivery of an ocular agent
CN101478949A (zh) * 2006-06-16 2009-07-08 瑞泽恩制药公司 适合玻璃体内施用的vegf拮抗剂的制剂
US20080131497A1 (en) 2006-09-28 2008-06-05 Perkins Walter R Formulations of DNase and Methods of Use Thereof
US20080118500A1 (en) * 2006-11-16 2008-05-22 Taiwan Liposome Company Sustained releasing composition via local injection for treating eye diseases
MY151191A (en) 2007-09-26 2014-04-30 Genentech Inc Novel antibodies
US8956600B2 (en) * 2009-08-10 2015-02-17 Taiwan Liposome Co. Ltd. Ophthalmic drug delivery system containing phospholipid and cholesterol

Also Published As

Publication number Publication date
NZ598656A (en) 2014-04-30
BR112012002981B8 (pt) 2021-05-25
TW201105350A (en) 2011-02-16
RU2012108888A (ru) 2013-09-20
HK1172564A1 (zh) 2013-04-26
CN105148278B (zh) 2019-11-05
US20200289652A1 (en) 2020-09-17
WO2011019410A1 (en) 2011-02-17
JP2013501786A (ja) 2013-01-17
BR112012002981B1 (pt) 2020-12-01
US20180169248A1 (en) 2018-06-21
KR101787775B1 (ko) 2017-10-18
KR101921852B1 (ko) 2018-11-23
EP3275445A1 (en) 2018-01-31
PT2813229T (pt) 2018-11-30
EP2813229B1 (en) 2018-08-29
ES2699249T3 (es) 2019-02-08
EP2464343A1 (en) 2012-06-20
EP2464343B1 (en) 2018-08-29
CN102573800B (zh) 2015-09-30
JP6243874B2 (ja) 2017-12-06
KR20170107106A (ko) 2017-09-22
US20150147320A1 (en) 2015-05-28
NZ623450A (en) 2015-06-26
CY1121467T1 (el) 2020-05-29
CY1121472T1 (el) 2020-05-29
US9987360B2 (en) 2018-06-05
TWI515008B (zh) 2016-01-01
PT2464343T (pt) 2018-12-05
EP2813229A1 (en) 2014-12-17
US8956600B2 (en) 2015-02-17
EP2464343A4 (en) 2013-01-23
CA2769929C (en) 2018-01-02
US11771766B2 (en) 2023-10-03
AU2010282983A1 (en) 2012-03-01
RU2572213C2 (ru) 2015-12-27
CN102573800A (zh) 2012-07-11
KR20120083316A (ko) 2012-07-25
JP5816623B2 (ja) 2015-11-18
ES2699178T3 (es) 2019-02-07
US20110033468A1 (en) 2011-02-10
ZA201201034B (en) 2015-06-24
DK2464343T3 (da) 2019-01-02
AU2010282983B2 (en) 2016-09-22
US10660960B2 (en) 2020-05-26
CN105148278A (zh) 2015-12-16
DK2813229T3 (en) 2018-12-17
CA2769929A1 (en) 2011-02-17
HK1214946A1 (zh) 2016-08-12
JP2015164961A (ja) 2015-09-17

Similar Documents

Publication Publication Date Title
BR112012002981A2 (pt) sistema de liberação de fármaco oftálmico contendo fosfolipídio e colesterol.
BRPI0917030A2 (pt) sistema de liberação de fármaco contendo progestina
BR112013012818A2 (pt) módulo medicamentoso e sistema de administração de fármaco
BRPI1013399A2 (pt) sistema de entrega de fármaco intervencional e métodos associados
BRPI1014139A2 (pt) sistema de liberação de fármacos compreendendo polioxazolina e um agente biotivo.
BRPI0913214A2 (pt) sistema de fornecimento de drogas transdérmico estabilizado
BRPI1014975A2 (pt) sistema de entrega de implante
DK2398500T3 (da) Glutathion-baseret lægemiddelafgivelsessystem
BR112013011702A2 (pt) sistema de distribuição de sirna in vivo à base de peptídeo
BRPI0818129A2 (pt) Sistema de transporte e administração de medicamento seguro
BR112012005660A2 (pt) conjunto de inserção de cartucho para sistema de distribuiçao de droga.
BRPI1010279A2 (pt) dispositivo de distribuição de fármaco
EP2401012A4 (en) ACTIVE RELEASE SYSTEM
BRPI1012730A2 (pt) dispositivo de distribuição de fármaco
BR112012000516A2 (pt) sistema de histórico médico
BRPI0920690A2 (pt) sistema de distribuição de stent restringível
BRPI0819245A2 (pt) sistema de distribuição transdérmica
BRPI1015947A2 (pt) dispositivos para distribuição de fármacos e sistemas e métodos relacionados
DK2493532T3 (da) Lægemiddelfremføringsanordning
BR112012000786A2 (pt) conjunto de mancal de impulso, sistema de direção, e dispositivo de envio de medicamento
BRPI1010237A2 (pt) dispositivo de distribuição de fármaco
LTPA2019508I1 (lt) Vaistų pristatymo sistema, skirta sunkiai vandenyje tirpstančių, farmaciškai aktyvių medžiagų, pateikimui
BR112012000799A2 (pt) dispositivo de distribuição de fármaco
BR112012006368A2 (pt) sistema de infusão de substâncias biológicas
IL227352A0 (en) A system for ocular administration of a drug

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06T Formal requirements before examination [chapter 6.20 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 01/12/2020, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 29/01/2010 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B25A Requested transfer of rights approved

Owner name: TAIWAN LIPOSOME CO. LTD (TW) ; TLC BIOPHARMACEUTICALS, INC. (US)